title: The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2.
abstract: The retinoblastoma (RB) gene product has been shown to restrict cell proliferation, promote cell differentiation, and inhibit apoptosis. Loss of RB function can induce both p53-dependent apoptosis and p53-independent apoptosis; little is known about the mechanisms of RB-regulated p53-independent apoptosis. Here we show that RB specifically activates transcription of the survival gene bcl-2 in epithelial cells but not in NIH 3T3 mesenchymal cells. This transcriptional activity is mediated by the transcription factor AP-2. By monitoring protein-DNA interactions in living cells using formaldehyde cross-linking and chromatin immunoprecipitation, we show that endogenous RB and AP-2 both bind to the same bcl-2 promoter sequence. In addition, we demonstrate that RB and AP-2 also bind to the E-cadherin gene promoter in vivo, consistent with regulation of this promoter by both AP-2 and RB in epithelial cells. This study provides evidence that RB activates bcl-2 and E-cadherin by binding directly to the respective promoter sequences and not indirectly by repressing an inhibitor. This recruitment is mediated by a transcription factor, in this case AP-2. For the first time, our results suggest a direct molecular mechanism by which RB might inhibit apoptosis independently of p53. The results are discussed in a context where RB and Bcl-2 contribute under nonpathological conditions to the maintenance of cell viability in association with a differentiated phenotype, contributing to the tumor suppressor function of RB and playing important roles in normal development.
authors.affiliation: Laboratoire Oncogenese, Differenciation et Transduction du Signal, CNRS UPR 9079, Institut Andre Lwoff, 94801 Villejuif, France. The Burnham Institute, La JollaCalifornia 92037, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Decary
authors.forename: Julien T
authors.initials: JT
authors.lastname: Decesse
authors.forename: Vasily
authors.initials: V
authors.lastname: Ogryzko
authors.forename: John C
authors.initials: JC
authors.lastname: Reed
authors.forename: Irina
authors.initials: I
authors.lastname: Naguibneva
authors.forename: Annick
authors.initials: A
authors.lastname: Harel-Bellan
authors.forename: Chantal E
authors.initials: CE
authors.lastname: Cremisi
mesh_terms: D000107:Acetylation; D015820:Cadherins / Q000235:genetics; D002460:Cell Line; D002843:Chromatin / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004847:Epithelial Cells / Q000166:cytology / Q000502:physiology*; D005786:Gene Expression Regulation; D017930:Genes, Reporter; D006657:Histones / Q000378:metabolism; D006801:Humans; D008957:Models, Genetic; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism*; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000378:metabolism*; D015533:Transcriptional Activation
chemical_list: D015820:Cadherins; D002843:Chromatin; D004268:DNA-Binding Proteins; D006657:Histones; D019253:Proto-Oncogene Proteins c-bcl-2; D011993:Recombinant Fusion Proteins; D016160:Retinoblastoma Protein; D050656:Transcription Factor AP-2; D014157:Transcription Factors